The race to develop safer, longer lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery.
To continue reading click here
Eli Lilly’s Adverum move: The future of ocular gene therapy at the 4th Ophthalmic Drug Delivery Summit
